Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Journal Volume
32
Journal Issue
9
Date Issued
2021-09
Author(s)
Sugawara, S
Lee, J-S
Kang, J-H
Kim, H R
Inui, N
Hida, T
Lee, K H
Yoshida, T
Tanaka, H
Yang, C-T
Nishio, M
Ohe, Y
Tamura, T
Yamamoto, N
Akamatsu, H
Namba, Y
Sumiyoshi, N
Nakagawa, K
Abstract
This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC).
Subjects
NSCLC; bevacizumab; nivolumab
SDGs
Type
journal article